- Capital Cube•7 days ago
Click here to see latest analysis*Disclaimer : This is as of previous day’s closeETF’s with exposure to Curis, Inc.Here are 5 ETF’s with the largest exposure to CRIS-US. Comparing the performance and risk of Curis, Inc. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns […] (Read more...) The post ETF’s with exposure to Curis, Inc. : July 19, 2016 appeared first on CapitalCube.
- American City Business Journals•last month
The field of so-called immuno-oncology drugs — those that enhance the immune system’s ability to fight cancer — has been a noisy one lately, with dozens of companies aiming to develop them after the U.S. approval of the first two in 2014. Opdivo, the Bristol-Meyer Squibb (BMY) drug for melanoma, lung and renal cancer, is expected to generate about $2.8 billion this year. Both are fruition of years of research into a new way of fighting cancer that’s intended to enhance existing cancer drugs.
After hours: 1.680.00 (0.00%) as of 5:18 PM EDT
|Bid||1.56 x 600|
|Ask||3.98 x 300|
|52wk Range||1.25 - 3.24|
|Day's Range||1.57 - 1.75|
|Avg Vol (3m)||417,787|
As of 4:00 PM EDT. Market closed.